Cellectis publie ses résultats financiers du premier trimestre 2023

May 4, 2023

https://www.globenewswire.com/news-release/2023/05/04/2662126/0/fr/Cellectis-publie-ses-r%C3%A9sultats-financiers-du-premier-trimestre-2023.html

NEW YORK, 04 mai 2023 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq : CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer des thérapies innovantes pour le traitement de maladies graves, présente aujourd’hui ses résultats pour le premier trimestre 2023.

Read more at globenewswire.com

Related news for (CLLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.